INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
|
|
- Aileen Fleming
- 8 years ago
- Views:
Transcription
1 INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL
2 QUESTION 1 1. ท านเคยเป นแพทย คนแรกท เร มให อ นส ล นร กษาในผ เป นเบาหวานท มาตรวจท OPD หร อไม A. YES B. NO
3 Normal Secretory Pattern of Insulin Total daily insulin requirement = unit/kg/d Prandial Insulin Insulin Level The 50/50 Rule Basal Insulin Breakfast Lunch Dinner S L E E P
4 Mrs B 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg. Currently on Glipizide 20 mg a day Metformin 2000 mg a day (used to on 2500 mg a day, but had diarrhea) Her last HbA1C 9%, FPG 220 mg/dl
5 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day (used to on 2500 mg a day, but had diarrhea) Pioglitazone 30 mg a day Her last HbA1C 9%, FPG 220 mg/dl QUESTION 2 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Lifestyle modification B. Add TZD C. Add AGI D. Add DPP-IV inhibitor E. Add insulin therapy
6 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day (used to on 2500 mg a day, but had diarrhea) Pioglitazone 30 mg a day Her last HbA1C 9%, FPG 220 mg/dl QUESTION 3 ถ าท านเล อกจะให อ นส ล นในผ ป วย รายน ท านจะเร มให อย างไร? A. Continue OHA + NPH 6 u B. Continue OHA + NPH 10 u C. Off SU, Cont MET + NPH 10 u D. Continue OHA + Glargine 10 u E. Off OHA + Mix insulin 15 u bid
7 Oral Hypoglycemic agents failure Add basal insulin
8 4T Trial STUDY METHOD Glycemic target: A1C 6.5% Basal group Add once (or twice) daily basal insulin* Add prandial insulin if glycaemic target not met 700 T2DM on OAD R Biphasic group Add twice daily biphasic insulin* Add midday prandial insulin if glycaemic target not met Prandial group Add thrice daily prandial insulin* Add basal insulin if glycaemic target not met Randomisation visit One year Two years Three years * progress to more intensive insulin regimen only if clinically necessary stop sulphonylurea if taken Holman RR.N Engl J Med 2009;361:1736
9 4T Trial EFFICACY % Attainment of Target HbA1c HbA1C < 6.5% HbA1C < 7.0% Biphasic group Prandial group Basal group
10 4T Trial ADVERSE EFFECTS Body weigh gain (kg) %Hypoglycemia (mod to severe) Biphasic Prandial Basal 0 Biphasic Prandial Basal Biphasic group Prandial group Basal group
11 STARTING WITH BASAL INSULIN ADVANTAGES 1 injection with no mixing Insulin pens for increased acceptance Slow, safe, and simple titration Low dosage Effective improvement in glycemic control Limited weight gain 6-37
12 BASAL INSULIN Which type? How to start? How to adjust?
13 TYPE OF BASAL INSULIN NPH insulin Onset: 1 1/ 2 hr Peak: 4-12 hr Duration: 24 hr Insulin Level Long-acting analogue insulin Onset: 2-3 hr Peak: none Duration: 24 hr Intermediate (NPH) Long (Glargine) Hours Long (Detemir)
14 TREAT-TO-TARGET TRIALS Insulin continually titrated to target: Fasting PG 100 mg/dl Insulin glargine once-daily (evening) n = 367 NPH once-daily (evening) n = 389 Insulin detemir twice-daily n = 237 NPH twice-daily n = 238 Riddle et al 2003 Hermansen et al 2006 Insulin continually titrated to target: Fasting and pre-dinner PG 108 mg/dl
15 Events per patient per year (%) Events per patient per year TREAT TO TARGET HbA 1c NPH + OAD Glargine + OAD Weeks NPH + OAD 8.5 Detemir + OAD Weeks Overall 21% risk reduction p < % risk reduction p <0.01 Nocturnal Hypoglycaemia Riddle et al Diabetes Care 2003;26: % risk reduction p < % risk reduction p < Overall Nocturnal Hypoglycaemia Hermansen et al. Diabetes Care 2006;29: 1269
16 Basal insulin Which type? How to start? How to adjust?
17 TREAT-TO-TARGET TRIALS Insulin continually titrated to target: Fasting PG 100 mg/dl The starting dose of both insulins was 10 IU Insulin glargine once-daily (evening) n = 367 NPH once-daily (evening) n = 389 Riddle et al 2003 Insulin detemir twice-daily n = 237 NPH twice-daily n = Starting 238 doses were 10 units/iu. If initial premeal PG <126 mg/dl or BMI was <26.0 kg/m2, starting doses were reduced to 6 units/iu. Insulin continually titrated to target: Fasting and pre-dinner PG 108 mg/dl Hermansen et al 2006
18 Basal insulin Which type? How to start? How to adjust?
19 1.2.3 STUDY: BASAL INSULIN PLUS 1, 2 OR 3 DOSES OF PRANDIAL INSULIN 785 Insulin naive type 2 diabetes (A1C 8.0%) Receiving 2 or 3 OHAs for 3 months A1C 7.0% RANDOMIZATION RUN-IN PHASE Add Insulin glargine OD 14 weeks Basal insulin + Prandial insulin 1 shot Basal insulin + Prandial insulin 2 shot Basal insulin + Prandial insulin 3 shot Davidson M et al. Endocr Pract 2011;17:395.
20 ADD BASAL INSULIN Start BASAL INSULIN 10 unit At 14-wk run-in 288/785 (37%) A1C < 7% HbA1c (%) Baseline 14-wk run-in
21 Maximum dose of Basal insulin Increase insulin dose is associated with weight gain Insulin dose <0.5 u/kg/d decrease HbA1c 0.5% for each increment in insulin dose equal to 0.1 u/kg/d Insulin dose >0.5 u/kg/d decrease HbA1c 0.5% for each increment in insulin dose equal to 0.2 u/kg/d Monnier L. Daibetes Metan 2006;32:7
22 TIP: BEDTIME INSULIN DAYTIME SULFONYLUREA Start NPH or non peak insulin 10 unit or unit/kg at bedtime Continue Oral hypoglycemic agent Titrate If FPG > 110 mg/dl x 2D 2 unit Keep FPG mg/dl Basal dose ~ unit/kg/d (~50% of Total daily dose)
23 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day (used to on 2500 mg a day, but had diarrhea) Pioglitazone 30 mg a day Her last HbA1C 9%, FPG 220 mg/dl QUESTION 2 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Lifestyle modification B. Add TZD C. Add AGI D. Add DPP-IV inhibitor E. Add insulin therapy
24 Efficacy of different OHAs Class of medicine Expected decrease in HbA 1C Biguanide % Sulfonylureas % Glinides* % TZDs % -glucosidase inhibitors % GLP-1 agonists % DPP4 inhibitors %
25 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day (used to on 2500 mg a day, but had diarrhea) Pioglitazone 30 mg a day Her last HbA1C 9%, FPG 220 mg/dl QUESTION 2 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Lifestyle modification B. Add TZD C. Add AGI D. Add DPP-IV inhibitor E. Add insulin therapy
26 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day (used to on 2500 mg a day, but had diarrhea) Pioglitazone 30 mg a day Her last HbA1C 9%, FPG 220 mg/dl QUESTION 3 ถ าท านเล อกจะให อ นส ล นในผ ป วย รายน ท านจะเร มให อย างไร? A. Continue OHA + NPH 6 u B. Continue OHA + NPH 10 u C. Off SU, Cont MET + NPH 10 u D. Continue OHA + Glargine 10 u E. Off OHA + Mix insulin 15 u bid
27 Mrs B Currently on Glipizide 20 mg a day Metformin 2000 mg a day NPH 26 unit per day Her last HbA1C 7.8%, FPG 100 mg/dl
28 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day NPH 26 unit per day Her last HbA1C 7.8%, FPG 100 mg/dl QUESTION 4 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Lifestyle modification B. Check insulin technique C. Add TZD D. Add DPP-IV inhibitor E. Switch to Glargine 20 u
29 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day NPH 26 unit per day Her last HbA1C 7.8%, FPG 100 mg/dl QUESTION 5 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Add TZD B. Add DPP-IV inhibitor C. Switch to Glargine 20 u D. Add RI 4 u at big meal E. Switch to Mix insulin 14 u bid
30 WHEN TO INTRODUCE MORE COMPLEX INSULIN REGIMENS? FPG is acceptable, but HbA1c is still high or post prandial higher than goal When aggressive titration is limited by hypoglycemia In insulin deficiency end of type 2 diabetes spectrum maximum dose of basal insulin
31 Oral Hypoglycemic agents failure Add basal insulin Switch to Premixed Insulin Add Prandial Insulin
32 572 T2DM 2-3 OADs A1C screening A1C randomization ALL TO TARGET STUDY DESIGN Current OADs 1 m BASAL INSULIN + 2 OADs 3m TTT FPG and pre prandial BG < 100 mg/dl A1C <6.5% BASALINSULIN + 2 OADs 60-week study Premix x 2 + met and/or TZD A1C > 7 BASAL + 1 PRANDIAL+ met and/or TZD B+P x1 + met/tzd 3 m B+P x2 + met/tzd A1C > 7 3 m A1C > 7 B+P x3 + met/tzd 3 m N=192 N=189 N=191 Riddle MC and Rosenstock J et al. ADA 2011, San Diego.
33 ALL TO TARGET EFFICACY A1C (%) % Patients with A1C <7% * 49 * * 24 * * * Premixed Basal + 1 shot * P < 0.05 vs. Premixed Basal shot 0 Baseline 60 weeks Premixed Basal + 1 shot Basal shot <7% without hypo
34 ALL TO TARGET SYMPTOMATIC HYPOGLYCEMIA 15 Event-rates per person-yr * * Premixed Basal + 1 shot * * Basal shot Basal + prandial Insulin had better efficacy and less hypoglycemia compare to Premixed * P < 0.05 vs. Premixed BG < 70 mg/dl BG < 50 mg/dl
35 Oral Hypoglycemic agents failure Add basal insulin Switch to Premixed Insulin Add Prandial Insulin
36 PRANDIAL INSULIN Rapid (Lispro, Aspart, Glulisine) Rapid-acting analogue insulin Onset: <1/2 hr Peak: 1 hr Duration: 3-4 hr Insulin Level Short (Regular) Regular insulin Onset: 1/2 hr Peak: 1-3 hr Duration: 6-8 hr Hours
37 1.2.3 STUDY: BASAL INSULIN PLUS 1, 2 OR 3 DOSES OF PRANDIAL INSULIN 785 Insulin naive type 2 diabetes (A1C 8.0%) Receiving 2 or 3 OHAs for 3 months A1C 7.0% RANDOMIZATION RUN-IN PHASE Add Insulin glargine OD 14 weeks Basal insulin + Prandial insulin 1 shot Basal insulin + Prandial insulin 2 shot Basal insulin + Prandial insulin 3 shot Davidson M et al. Endocr Pract 2011;17:395.
38 1.2.3 STUDY: BASAL INSULIN PLUS 1, 2 OR 3 DOSES OF PRANDIAL INSULIN Definition of Main meal Start: 1/10 of total daily dose of BASAL INSULIN Titration Preprandial SMBG during the preceeding 7 calendar days Weekly titration
39 A1C c (%) STUDY: BASAL INSULIN PLUS 1, 2 OR 3 DOSES OF PRANDIAL INSULIN Evolution of A1C in the randomized BASAL (alone) BASAL plus PRANDIAL (patients with A1C >7%) PRANDIAL 1x PRANDIAL 2x PRANDIAL 3x Run in Randomization Wk 8 Wk 16 Wk 24 A1C in all subjects (n=785) = 9.8 at run-in and 7.3 at randomization
40 Mean body weight change from baseline (kg) Confirmed symptomatic hypo (event/patient-year) Severe or serious hypo (event/patient-year) STUDY: BASAL INSULIN PLUS 1, 2 OR 3 DOSES OF PRANDIAL INSULIN p= x1 x2 x3 PRANDIAL 0 x1 x2 x3 PRANDIAL 0.00 x1 x2 x3 PRANDIAL p=ns for all other pairwise comparisons Basal + 1, 2 or 3 prandial Insulin had similar efficacy stepwise approach
41 Oral Hypoglycemic agents failure Add basal insulin Add Prandial insulin at main meal OR breakfast
42 TIPS: ADDING SINGLE PRANDIAL INSULIN INJECTION Add with the main meal Starting dose 10% of total daily dose, not less than 4 unit/meal Monitor pre-prandial glucose of next meal Target SMBG pre-prandial < mg/dl, bedtime mg/dl Titration dose, <10 u dose, u dose, >20 u add 1 unit add 2 unit add 3 unit
43 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Glipizide 20 mg a day Metformin 2000 mg a day NPH 26 unit per day Her last HbA1C 7.8%, FPG 100 mg/dl QUESTION 5 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Add TZD B. Add DPP-IV inhibitor C. Switch to Glargine 20 u D. Add RI 4 u at big meal E. Switch to Mix insulin 14 u bid
44 Mrs B Currently on Metformin 2000 mg a day NPH 30 unit per day RI 10 unit at lunch time Her last HbA1C 8.1%, FPG 130 mg/dl
45 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Metformin 2000 mg a day NPH 30 unit per day RI 10 unit at lunch time Her last HbA1C 8.1%, FPG 130 mg/dl QUESTION 6 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Add RI 4 u at dinner B. Switch to Mix insulin 15 u bid C. Switch to Mix insulin 20 u at breakfast and 10 u at dinner
46 Oral Hypoglycemic agents failure Add basal insulin Switch to Premixed Insulin Add Prandial Insulin
47 Premixed Insulin Human insulin 70/30 Insulin analog 75/25 Insulin analog 70/30
48 Insulin Effect Mixtures of Pre-meal Insulin Regular/NPH Combined effect B L S HS B
49 Starting dose? Usually conventional initial approach to dosing premixed insulins in general practice is to prescribe a ratio of 2/3 of the total daily insulin dose in the morning before breakfast and 1/3 in the evening before dinner.
50 PREMIXED INSULIN DOSING IN ACTUAL PRACTICE: 2/3 IN AM, 1/3 IN PM, OR 50-50? retrospective, observational, descriptive study was designed to examine the use of premixed insulins in a community-based endocrinology practice to analyze the ratio, for morning and evening doses of premixed insulin. the premixed insulin dosing ratio of evening dose to TDD significantly differs from the standard value of 0.33 and is on average close to 0.5 or 50%
51 How about the SU, should we stop? The only consistent advantage of continue SU is: Reduced insulin dose requirements, which may result in less daily injections Easier dose titration Improved compliance These potential benefits must be balanced against the side effects
52 Dose Titration Blood Glucose Adjust Insulin* Prebreakfast <70 mg/dl Decrease PM 1-2 U mg/dl Increase PM 1-2 U >250 mg/dl Increase PM 2-4 U Presupper <70 mg/dl Decrease AM 1-2 U mg/dl Increase AM 1-2 U > 250 mg/dl Increase AM 2-4 U Person J. Diabet Educat 2006;32:195
53 60 years old Thai female Type 2 DM Diagnosed 10 years ago Co-morbid diseases: HT, Dyslipidemia BW 60 kg Currently on Metformin 2000 mg a day NPH 30 unit per day RI 10 unit at lunch time Her last HbA1C 8.1%, FPG 130 mg/dl QUESTION 6 ท านจะให การร กษาผ ป วยรายน อย างไร? A. Add RI 4 u at dinner B. Switch to Mix insulin 15 u bid C. Switch to Mix insulin 20 u at breakfast and 10 u at dinner
54 THANK YOU
Therapy Insulin Practical guide to Health Care Providers Quick Reference F Diabetes Mellitus in Type 2
Ministry of Health, Malaysia 2010 First published March 2011 Perkhidmatan Diabetes dan Endokrinologi Kementerian Kesihatan Malaysia Practical guide to Insulin Therapy in Type 2 Diabetes Mellitus Quick
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationInsulin Therapy In Type 2 DM. Sources of support. Agenda. Michael Fischer, M.D., M.S. The underuse of insulin Insulin definition and types
Insulin Therapy In Type 2 DM Michael Fischer, M.D., M.S. Sources of support NaRCAD is supported by a grant from the Agency for Healthcare Research and Quality My current research projects are funded by
More informationWorkshop A Tara Kadis
Workshop A Tara Kadis Considerations/barriers in decision making about insulin verses GLP-1 use in people with type 2 diabetes Which Insulin regimes should we consider? Diabetes is a progressive multi-system
More informationAlgorithms for Glycemic Management of Type 2 Diabetes
KENTUCKY DIABETES NETWORK, INC. Algorithms for Glycemic Management of Type 2 Diabetes The Diabetes Care Algorithms for Type 2 Diabetes included within this document are taken from the American Association
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationA Simplified Approach to Initiating Insulin. 4. Not meeting glycemic goals with oral hypoglycemic agents or
A Simplified Approach to Initiating Insulin When to Start Insulin: 1. Fasting plasma glucose (FPG) levels >250 mg/dl or 2. Glycated hemoglobin (A1C) >10% or 3. Random plasma glucose consistently >300 mg/dl
More informationTYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES
TYPE 2 DIABETES SEQUENTIAL INSULIN STRATEGIES Non-insulin regimes Basal insulin only (usually with oral agents) Number of injections 1 Regimen complexity Low Basal insulin +1 meal-time rapidacting insulin
More informationInsulin: Breaking Barriers Enhancing Therapies. Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net
Insulin: Breaking Barriers Enhancing Therapies Jerry Meece, RPh, FACA, CDE jmeece12@cooke.net Questions To Address Who are candidates for insulin? When do we start insulin? How do the different types of
More informationInsulin Therapy. Endocrinologist. H. Delshad M.D. Research Institute For Endocrine Sciences
Insulin Therapy H. Delshad M.D Endocrinologist Research Institute For Endocrine Sciences Primary Objectives of Effective Management A1C % 9 8 Diagnosis SBP mm Hg LDL mg/dl 7 145 130 140 100 Reduction of
More informationPresented By: Dr. Nadira Husein
Presented By: Dr. Nadira Husein I have no conflict of interest Disclosures I have received honoraria/educational grants from the following: Novo Nordisk, Eli Lilly, sanofi-aventis, Novartis, Astra Zeneca,
More informationInsulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults
Insulin Algorithm for Type 2 Diabetes Mellitus in Children and Adults Stock # 45-11647 Revised 10/28/10 Glycemic Goals 1,2 Individualize goal based on patient risk factors A1c 6%
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationInsulin Therapy for Optimizing Glycemic Control in Type 2 DM. Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013
Insulin Therapy for Optimizing Glycemic Control in Type 2 DM Puntip Tantiwong Department of Medicine Maharat Nakhon Ratchasima Hospital 22 May 2013 Case 1 A 45 years-old Thai female with T2DM for 3 years
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationIntensive Insulin Therapy in Diabetes Management
Intensive Insulin Therapy in Diabetes Management Lillian F. Lien, MD Medical Director, Duke Inpatient Diabetes Management Assistant Professor of Medicine Division of Endocrinology, Metabolism, & Nutrition
More informationINPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco
INPATIENT DIABETES MANAGEMENT Robert J. Rushakoff, MD Professor of Medicine Director, Inpatient Diabetes University of California, San Francisco CLINICAL RECOGNITION Background: Appropriate inpatient glycemic
More informationInsulin switch & Algorithms Rotorua GP CME June 2011. Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB
Insulin switch & Algorithms Rotorua GP CME June 2011 Kingsley Nirmalaraj FRACP Endocrinologist BOPDHB Goal of workshop Insulin switching make the necessary move Ensure participants are confident with Recognising
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationADJUSTING INSULIN DOSES CONFLICTS OF INTEREST
ADJUSTING INSULIN DOSES CONFLICTS OF INTEREST Vahid Mahabadi, MD Research grants from Sanofi and Amylin Pharmaceutical Companies Mayer B. Davidson, MD Advisory Board Sanofi Pharmaceutical Company Chief
More informationINSULIN ALGORITHM FOR TYPE 2 DIABETES MELLITUS IN CHILDREN 1 AND ADULTS
Publication # 45-11647 Targets*
More informationInitiating & titrating insulin & switching in General Practice Workshop 1
Initiating & titrating insulin & switching in General Practice Workshop 1 Workshop goal To make participants comfortable in the timely initiation and titration of insulin Progression of Type 2 Diabetes
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationIMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL
464 IMPROVED METABOLIC CONTROL WITH A FAVORABLE WEIGHT PROFILE IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH INSULIN GLARGINE (LANTUS ) IN CLINICAL PRACTICE STEPHAN A SCHREIBER AND ANIKA RUßMAN ABSTRACT
More informationPresent and Future of Insulin Therapy: Research Rationale for New Insulins
Present and Future of Insulin Therapy: Research Rationale for New Insulins Current insulin analogues represent an important advance over human insulins, but clinically important limitations of these agents
More informationDiabetes and the Elimination of Sliding Scale Insulin. Date: April 30 th 2013. Presenter: Derek Sanders, D.Ph.
Diabetes and the Elimination of Sliding Scale Insulin Date: April 30 th 2013 Presenter: Derek Sanders, D.Ph. Background Information Epidemiology and Risk Factors Diabetes Its Definition and Its Impact
More informationNCT00272090. sanofi-aventis HOE901_3507. insulin glargine
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: Generic drug name:
More informationSession 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives
Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationInsulin Initiation and Intensification
Insulin Initiation and Intensification ANDREW S. RHINEHART, MD, FACP, CDE MEDICAL DIRECTOR AND DIABETOLOGIST JOHNSTON MEMORIAL DIABETES CARE CENTER Objectives Understand the pharmacodynamics and pharmacokinetics
More informationSession 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives
Session 5: Insulin: Tried and True - Update on Best Practices in Clinical Use and Patient Adherence Learning Objectives 1. Design strategies to help patients overcome cultural barriers to using insulin,
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationMany patients with type 2 diabetes will ultimately need
SUPPLEMENT TO JAPI april 2011 VOL. 59 17 Insulin Initiation and Intensification: Insights from New Studies Ajay Kumar 1, Sanjay Kalra 2 Abstract Tight glycemic control is central to reducing the risk of
More informationNovel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety
Novel Trial Designs in T2D to Satisfy Regulatory Requirements for CV Safety Anders Svensson MD, PhD Head of Global Clinical Development Metabolism, F Hoffmann LaRoche Ltd. Basel, Switzerland Overview of
More informationStarting or Changing Insulin Therapy For the Generalist Physician
Starting or Changing Insulin Therapy For the Generalist Physician SGIM National Meeting 2008 DC Dugdale, MD, FACP Division of GIM, University of Washington Dawn E. DeWitt MD, FACP, FRACP University of
More informationCLASS OBJECTIVES. Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies
Insulins CLASS OBJECTIVES Describe the history of insulin discovery List types of insulin Define indications and dosages Review case studies INVENTION OF INSULIN 1921 The first stills used to make insulin
More informationAre insulin analogs worth their cost in type 2 diabetes?
Keystone, Colorado 2012 Are insulin analogs worth their cost in type 2 diabetes? Dr. Amanda Adler Consultant Physician, Institute of Metabolic Sciences Addenbrooke s Hospital, Cambridge Chair, Technology
More informationType 2 Diabetes Adult Outpatient Insulin Guidelines Sutter Medical Foundation. February 2011.
Type 2 Diabetes Adult Outpatient Insulin Guidelines. GENERAL RECOMMENDATIONS Start insulin if A1C and glucose levels are above goal despite optimal use of other diabetes medications. (Consider insulin
More informationType 2 diabetes mellitus
Type 2 diabetes mellitus CLINICAL PRACTICE Management Guidelines for initiating insulin therapy BACKGROUND Insulin is often indicated for patients with suboptimally controlled type 2 diabetes mellitus,
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationPrior Authorization Guideline
Prior Authorization Guideline Guideline: PC - Apidra, Levemir Therapeutic Class: Hormones and Synthetic Substitutes Therapeutic Sub-Class: Antidiabetic Agents Client: CA, CO, NV, OK, OR, WA and AZ Approval
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
PL Detail-Document #300128 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER January 2014 Initiation and Adjustment of Insulin Regimens for Type
More informationStarting Insulin. Disclosures. Starting Insulin. Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres
Starting Insulin Ronnie Aronson MD, FRCPC, FACE Executive Director, LMC Endocrinology Centres Disclosures Scientific Consultant Abbott, AstraZeneca, GSK, Merck, Sanofi-Aventis, Janssen- Ortho, Servier
More informationInsulin/Diabetes Calculations
Insulin/Diabetes Calculations Dr. Aipoalani St Lukes Endocrinology Goals Describe various calculations for insulin dosing Understand importance of the total daily dose (TDD) of insulin Be able to calculate
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationAgainst All Odds: Improving Insulin Use in T2DM Through Individualized Clinical Decision Making
SESSION 3 10:30am 12pm Against All Odds: Improving Insulin Use in T2DM Through Individualized Clinical Decision Making SPEAKERS Frank Lavernia, MD George Dailey III, MD Carol Wysham, MD Presenter Disclosure
More informationEveryday Practice: Diabetes Mellitus
THE NATIONAL MEDICAL JOURNAL OF INDIA VOL. 20, NO. 5, 2007 245 Everyday Practice: Diabetes Mellitus Insulin therapy for patients with type 2 diabetes mellitus NISHA R. S., E. BHATIA INTRODUCTION India
More informationInsulin therapy in type 2 diabetes When and how? Disclosures. Learning Objectives. None relevant to today s talk
Insulin therapy in type 2 diabetes When and how? Cecilia C Low Wang, MD Univ Colorado AMC SOM Department of Medicine Division of Endocrinology, Metabolism, and Diabetes Disclosures None relevant to today
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationLipodystrophy: Metabolic and Clinical Aspects. Resource Room Slide Series
Lipodystrophy: Metabolic and Clinical Aspects Resource Room Slide Series Current Thinking About the Diagnosis and Treatment of the Insulin-Resistant State: How to Use Insulin Therapy Irl B. Hirsch, MD
More informationDr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationScottish Medicines Consortium
Scottish Medicines Consortium insulin glulisine for subcutaneous injection 100 units/ml (Apidra ) No. (298/06) Sanofi Aventis 4 August 2006 The Scottish Medicines Consortium (SMC) has completed its assessment
More information(30251) Insulin SQ Prandial Carbohydrate
Diagnosis Patient MUST BE educated using carbohydrate counting for prial insulin coverage before hospitalization to be eligible for this order set Nursing Metered Glucose (Single Select Section) Metered
More informationShanmugasundar G., Anil Bhansali, Rama Walia, Pinaki Dutta & Vimal Upreti
Indian J Med Res 135, January 2012, pp 78-83 Comparison of thrice daily biphasic human insulin (30/70) versus basal detemir & bolus aspart in patients with poorly controlled type 2 diabetes mellitus A
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationMost patients with T2DM will eventually require insulin therapy. ADA Glycemic Control Targets. What are some of the obstacles?
ADA Glycemic Control Targets A1C < 7% Preprandial plasma glucose 70-130 mg/dl Postprandial plasma glucose (PPG)
More informationType 2 Diabetes: When to Initiate And Intensify Insulin Therapy. Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB
Type 2 Diabetes: When to Initiate And Intensify Insulin Therapy Julie Bate on behalf of: Dr John Wilson Endocrinologist Capital and Coast DHB Declarations I have received travel funding and speaker fees
More informationCalculating Insulin Dose
Calculating Insulin Dose First, some basic things to know about insulin: Approximately 40-50% of the total daily insulin dose is to replace insulin overnight, when you are fasting and between meals. This
More informationInsulin initiation in type 2 diabetes: Experience and insights
Insulin initiation in type 2 diabetes: Experience and insights Joan Everett A diagnosis of type 2 diabetes can be devastating for the individual and their family. Furthermore, many people with diabetes
More informationPrinciples on Insulin Treatments. Insulin & Type 2 Diabetes. Natural History of Type 2 Diabetes. Why Consider Insulin Early?
Principles on Treatments & Type 2 Diabetes Jessica Castle, MD Assistant Professor, OHSU Harold Schnitzer Diabetes Health Center Natural History of Type 2 Diabetes Severity of Diabetes UKPDS: Over Time,
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More information2/24/2015. Collaborative Care. Population Management. Population Management. Population Management
Collaborative Care Optimizing Collaboration between the Primary Care Provider and the Specialist for Co-Managing High Risk Patients John Devlin, MD Endocrinologist A team with a shared mission using improved
More informationInsulin therapy in various type 1 diabetes patients workshop
Insulin therapy in various type 1 diabetes patients workshop Bruce H.R. Wolffenbuttel, MD PhD Dept of Endocrinology, UMC Groningen website: www.umcg.net & www.gmed.nl Twitter: @bhrw Case no. 1 Male of
More informationInsulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy
Insulin Analogues versus Pump Therapy in Type 2 Diabetes: Benefits from Pump Therapy Eric RENARD, MD, PhD Endocrinology Dept, Lapeyronie Hospital Montpellier, France e-renard@chu-montpellier.fr Type 2
More informationTen Ways to Prevent Insulin-Use Errors in Your Hospital. ASHP Research and Education Foundation May 14, 2014
Ten Ways to Prevent Insulin-Use Errors in Your Hospital ASHP Research and Education Foundation May 14, 2014 To Ask Questions and Adjust the Control Panel Expand or Collapse Type your question here Faculty
More informationCochrane Quality and Productivity topics
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus NICE has developed the Cochrane Quality and Productivity (QP) topics to help the NHS identify practices
More informationGlycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol
Glycemic Control Initiative: Insulin Order Set Changes Hypoglycemia Nursing Protocol Ruth LaCasse Kalish, RPh Department of Pharmacy Objectives Review the current practice at UConn Health with sliding
More informationGlycaemic Control in Adults with Type 1 Diabetes
Glycaemic Control in Adults with Type 1 Diabetes Aim(s) and objective(s) This document aims to provide guidance on good clinical practice in managing glycaemic control in adult patients with Type 1 Diabetes
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationHow To Initiate Insulin
Initiation and Titration of Insulin Analogs in the Patient with Type 2 Diabetes Supported by an educational grant from Novo Nordisk Inc. This program is supported by an educational grant from Novo Nordisk
More informationThere seem to be inconsistencies regarding diabetic management in
Society of Ambulatory Anesthesia (SAMBA) Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Review of the consensus statement and additional
More informationGlobal Guideline for Type 2 Diabetes
INTERNATIONAL DIABETES FEDERATION, 2005 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes Chapter 10: Glucose control: insulin therapy Copyright All rights reserved. No part of this publication
More informationLeicestershire Diabetes Guidelines: Insulin Therapy
Endorsed by Leicestershire Medicines Strategy Group Leicestershire Diabetes Guidelines: Insulin Therapy These guidelines are designed for use by those trained and competent in insulin initiation and management
More informationThe first injection of insulin was given on
EFFECTIVE USE OF INSULIN THERAPY IN TYPE 2 DIABETES * Bernard Zinman, MDCM ABSTRACT Type 2 diabetes is a progressive disease; an individual s ability to secrete insulin in increasing amounts to overcome
More informationThe U.K. Prospective Diabetes Study
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Initiating Insulin Therapy in Type 2 Diabetes A comparison of biphasic and basal insulin analogs PHILIP RASKIN, MD 1 ELSIE ALLEN, MD 2 PRISCILLA
More informationInsulin therapy in type 2 diabetes
Med Clin N Am 88 (2004) 865 895 Insulin therapy in type 2 diabetes Trent Davis, MD, Steven V. Edelman, MD* Section of Diabetes/Metabolism, Veterans Affairs San Diego HealthCare System, 3350 La Jolla Village
More informationStarting patients on the V-Go Disposable Insulin Delivery Device
Starting patients on the V-Go Disposable Insulin Delivery Device A simple guide for your practice For adult patients with Type 2 diabetes on basal insulin who need to take the next step Identify appropriate
More informationIntensifying Insulin In Type 2 Diabetes
Intensifying Insulin In Type 2 Diabetes Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine University of North Dakota School of Medicine and Health Sciences Assistant
More informationTreatment of patients with type 2 diabetes: from text book therapy to personalized medicine
1 Treatment of patients with type 2 diabetes: from text book therapy to personalized medicine BruceH H.R. Wolffenbuttel, MDPhD Professor of Endocrinology & Metabolism University Medical Center Groningen
More informationBASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS
BASAL BOLUS INSULIN FOR MEDICAL- SURGICAL INPATIENTS C O N T A C T D I A B E T E S S E R V I C E S F O R M O R E I N F O R M A T I O N 8 4 7-9 1 7-6 9 0 7 THIS SLIDE PRESENTATION WAS PREPARED BY SUE DROGOS,
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
Page 1 of 5 PURPOSE To assure that DOP inmates with Diabetes, who require insulin therapy, are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow
More informationManagement of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationEmerging Challenges in Primary Care: 2016. Insulin Management of Type 2 Diabetes: Designing Treatments and Overcoming Barriers
Emerging Challenges in Primary Care: 2016 Insulin Management of Type 2 Diabetes: Designing Treatments and Overcoming Barriers Faculty Richard S. Beaser, MD Senior Staff Physician Chair, Continuing Medical
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationTYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD. www.diabetesclinic.
TYPE2DIABETES INSULIN TREATMENT 2009 UPDATE ON A HEALTHCARE PROFESSIONAL S GUIDE TO TREATMENT BY J. ROBIN CONWAY, MD www.diabetesclinic.ca Author: Dr. Robin Conway Note to readers The contents herein represent
More informationThe U.K. Prospective Diabetes Study
Clinical Care/Education/Nutrition O R I G I N A L A R T I C L E Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes Comparison of two treatment algorithms using insulin glargine
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationBIAsp30 A 1 chieve Tehran 31 July 2015
BIAsp30 A 1 chieve Tehran 31 July 2015 Beginning insulin with biphasic insulin aspart 30: experience from the A 1 chieve study Professor Philip Home Newcastle University Presenter and sponsor duality of
More informationMultiple-dose insulin injection therapy in patients with type 2 diabetes using a basal-bolus regimen, team management, and nutrition education
Multiple-dose insulin injection therapy in patients with type 2 diabetes using a basal-bolus regimen, team management, and nutrition education Alison Baldwin, BS University of South Carolina School of
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationA new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration
of nurse A new insulin order form should be completed for subsequent changes to type of insulin and/or frequency of administration 1. Check times for point of care meter blood glucose testing. Pre-Breakfast
More informationInsulin. Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs
Insulin Regimens Characteristics / categorization Pharmacokinetics / pharmacodynamics Adverse effects Compatibility Costs Insulins Rapid-acting Inhaled Short-acting Basal/ Intermediate Basal Pre-mixed
More informationSUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS
SUBJECT: DIABETES MEDICATION MANAGEMENT PROTOCOLS PURPOSE To establish a process that will enable Certified Diabetes Educators (CDE) and/or staff with Board Certification in Advanced Diabetes Management
More informationInsulin onset, peak and duration of action
Insulin onset, peak and duration of action Insulin was first discovered in the early 190 s. Before then, diabetes could not be treated. Insulin was then taken from cow and pig pancreases, but nearly all
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationINTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL
INTERNAL MEDICINE RESIDENTS NOON CONFERENCE: INPATIENT GLYCEMIC CONTROL Presented by: Leyda Callejas PGY5 Endocrinology, Diabetes and Metabolism Acknowledgements: Dr. P Orlander Dr. V Lavis Dr. N Shah
More informationShort-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis
ORIGINAL ARTICLE doi: 10.1111/j.1463-1326.2008.00934.x Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis E. Mannucci, M. Monami and N. Marchionni Department of
More information